Volume 4, Number 6, Supplement 3 (June 2007) |
| From Early to Metastatic Colorectal Cancer: Decision Points Along the Treatment Continuum |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of New York Medical College (NYMC) and the Continuing Education Alliance. To receive CME credit, print out, complete, and mail the evaluation form to New York Medical College, Office of Continuing Medical Education, Vosburgh Pavilion, Room 229, Valhalla, NY 10595, prior to June 15, 2008. |
|
Information About This CME Activity
Target Audience • Faculty Affiliations • Learning Objectives • Faculty Disclosures • Americans With Disabilities Act • How to Receive Credit • Disclaimer • About National Peer Reviews in Colorectal Cancer
| Release date: June 15, 2007 • Expiration date: June 15, 2008 |
|
Contents |
5 |
|
Selection of patients with stage II disease for adjuvant therapy Al B. Benson III, MD Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
|
11 |
|
Rational treatment planning for isolated, potentially curable liver metastases Charles D. Blanke, MD Oregon Health & Science University, Portland, OR
|
17 |
|
Expanded treatment options in metastatic disease Charles S. Fuchs, MD, MPH Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
|
24 |
|
Rational treatment planning for metastatic disease Axel Grothey, MD Mayo Clinic Rochester, Rochester, MN
|
30 |
|
Self-assessment questions
|
32 |
|
Evaluation form and answer grid
|
This activity is supported by an unrestricted educational grant from Pfizer Inc. |
© 2007 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.
The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement. |
51 kb